

Christophe Legendre

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3230168/publications.pdf>

Version: 2024-02-01

192
papers

10,818
citations

34076

52
h-index

36008

97
g-index

208
all docs

208
docs citations

208
times ranked

9113
citing authors

#	ARTICLE	IF	CITATIONS
1	Complement-Binding Anti-HLA Antibodies and Kidney-Allograft Survival. <i>New England Journal of Medicine</i> , 2013, 369, 1215-1226.	13.9	746
2	Valacyclovir for the Prevention of Cytomegalovirus Disease after Renal Transplantation. <i>New England Journal of Medicine</i> , 1999, 340, 1462-1470.	13.9	681
3	Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. <i>Kidney International</i> , 2015, 87, 1061-1073.	2.6	342
4	Antibody-mediated vascular rejection of kidney allografts: a population-based study. <i>Lancet, The</i> , 2013, 381, 313-319.	6.3	308
5	Outcome of Subclinical Antibody-Mediated Rejection in Kidney Transplant Recipients with Preformed Donor-Specific Antibodies. <i>American Journal of Transplantation</i> , 2009, 9, 2561-2570.	2.6	290
6	Each additional hour of cold ischemia time significantly increases the risk of graft failure and mortality following renal transplantation. <i>Kidney International</i> , 2015, 87, 343-349.	2.6	287
7	IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 293-304.	3.0	244
8	Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1721-1731.	3.0	243
9	HARMFUL LONG-TERM IMPACT OF HEPATITIS C VIRUS INFECTION IN KIDNEY TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 1998, 65, 667-670.	0.5	233
10	Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial. <i>American Journal of Kidney Diseases</i> , 2016, 68, 84-93.	2.1	230
11	Eculizumab for Atypical Hemolytic Uremic Syndrome Recurrence in Renal Transplantation. <i>American Journal of Transplantation</i> , 2012, 12, 3337-3354.	2.6	223
12	Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1912-1923.	3.0	208
13	Analyses of the short- and long-term graft survival after kidney transplantation in Europe between 1986 and 2015. <i>Kidney International</i> , 2018, 94, 964-973.	2.6	198
14	Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1979-1991.	3.0	193
15	Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study. <i>BMJ: British Medical Journal</i> , 2019, 366, 14923.	2.4	191
16	Factors influencing long-term outcome after kidney transplantation. <i>Transplant International</i> , 2014, 27, 19-27.	0.8	176
17	A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. <i>Science Translational Medicine</i> , 2014, 6, 256ra136.	5.8	172
18	New insights into postrenal transplant hemolytic uremic syndrome. <i>Nature Reviews Nephrology</i> , 2011, 7, 23-35.	4.1	169

#	ARTICLE	IF	CITATIONS
19	Long term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study. <i>BMJ, The</i> , 2015, 351, h3557.	3.0	146
20	Cytomegalovirus Incidence Between Everolimus Versus Mycophenolate in De Novo Renal Transplants: Pooled Analysis of Three Clinical Trials. <i>American Journal of Transplantation</i> , 2011, 11, 2453-2462.	2.6	135
21	Combined Posttransplant Prophylactic IVIg/Anti-CD 20/Plasmapheresis in Kidney Recipients With Preformed Donor-Specific Antibodies: A Pilot Study. <i>Transplantation</i> , 2010, 89, 1403-1410.	0.5	133
22	Disparities in Acceptance of Deceased Donor Kidneys Between the United States and France and Estimated Effects of Increased US Acceptance. <i>JAMA Internal Medicine</i> , 2019, 179, 1365.	2.6	125
23	Kaposi sarcoma in transplantation. <i>Transplantation Reviews</i> , 2008, 22, 252-261.	1.2	123
24	Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients. <i>Kidney International</i> , 2019, 96, 189-201.	2.6	117
25	A Simple Clinico-Histopathological Composite Scoring System Is Highly Predictive of Graft Outcomes in Marginal Donors. <i>American Journal of Transplantation</i> , 2008, 8, 2325-2334.	2.6	116
26	Sirolimus Conversion for Patients with Posttransplant Kaposi's Sarcoma. <i>American Journal of Transplantation</i> , 2006, 6, 2164-2168.	2.6	114
27	Urinary C-X-C Motif Chemokine 10 Independently Improves the Noninvasive Diagnosis of Antibody-Mediated Kidney Allograft Rejection. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2840-2851.	3.0	112
28	Value of Donor-Specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 702-715.	3.0	111
29	HUMAN HERPES VIRUS-8 AND OTHER RISK FACTORS FOR KAPOSI'S SARCOMA IN KIDNEY TRANSPLANT RECIPIENTS ¹ . <i>Transplantation</i> , 1999, 67, 1236-1242.	0.5	107
30	Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated With Belatacept. <i>Transplantation</i> , 2021, 105, e94-e95.	0.5	105
31	mTOR inhibitors-induced proteinuria: mechanisms, significance, and management. <i>Transplantation Reviews</i> , 2008, 22, 125-130.	1.2	103
32	Specificity of Histological Markers of Long-Term CNI Nephrotoxicity in Kidney Transplant Recipients Under Low-Dose Cyclosporine Therapy. <i>American Journal of Transplantation</i> , 2011, 11, 2635-2646.	2.6	101
33	Effects of vitamin D supplementation on the calcium-phosphate balance in renal transplant patients. <i>Kidney International</i> , 2009, 75, 646-651.	2.6	99
34	Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study. <i>American Journal of Transplantation</i> , 2019, 19, 3018-3034.	2.6	97
35	Prognostic Value of Quantitative Kaposi Sarcoma-Associated Herpesvirus Load in Posttransplantation Kaposi Sarcoma. <i>Journal of Infectious Diseases</i> , 2002, 186, 110-113.	1.9	93
36	C5 nephritic factors drive the biological phenotype of C3 glomerulopathies. <i>Kidney International</i> , 2017, 92, 1232-1241.	2.6	93

#	ARTICLE	IF	CITATIONS
37	Donor-Specific Antibodies Accelerate Arteriosclerosis after Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 975-983.	3.0	88
38	Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study. <i>American Journal of Transplantation</i> , 2017, 17, 1370-1379.	2.6	85
39	Weak antibody response to three doses of mRNA vaccine in kidney transplant recipients treated with belatacept. <i>American Journal of Transplantation</i> , 2021, 21, 4043-4051.	2.6	84
40	Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1603-1613.	3.0	83
41	A useful scoring system for the prediction and management of delayed graft function following kidney transplantation from cadaveric donors. <i>Kidney International</i> , 2014, 86, 1130-1139.	2.6	82
42	Improving Outcomes for Solid-Organ Transplant Recipients At Risk from Cytomegalovirus Infection: Late-Onset Disease and Indirect Consequences. <i>Clinical Infectious Diseases</i> , 2008, 46, 732-740.	2.9	81
43	Recurrence of nephrotic syndrome after transplantation in a mixed population of children and adults: course of glomerular lesions and value of the Columbia classification of histological variants of focal and segmental glomerulosclerosis (FSGS). <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1321-1328.	0.4	81
44	T cell-mediated rejection is a major determinant of inflammation in scarred areas in kidney allografts. <i>American Journal of Transplantation</i> , 2018, 18, 377-390.	2.6	76
45	Donor-Estimated GFR as an Appropriate Criterion for Allocation of ECD Kidneys into Single or Dual Kidney Transplantation. <i>American Journal of Transplantation</i> , 2009, 9, 2542-2551.	2.6	75
46	B7-1 Blockade Does Not Improve Post-Transplant Nephrotic Syndrome Caused by Recurrent FSGS. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 2520-2527.	3.0	75
47	COVID-19 severity in kidney transplant recipients is similar to nontransplant patients with similar comorbidities. <i>American Journal of Transplantation</i> , 2021, 21, 1285-1294.	2.6	69
48	Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies. <i>American Journal of Transplantation</i> , 2019, 19, 2865-2875.	2.6	67
49	Differences in the frequency and function of HHV8-specific CD8 T cells between asymptomatic HHV8 infection and Kaposi sarcoma. <i>Blood</i> , 2006, 108, 3871-3880.	0.6	66
50	Kidney Transplant in Black Recipients: Are African Europeans Different from African Americans?. <i>American Journal of Transplantation</i> , 2005, 5, 2682-2687.	2.6	64
51	Response to treatment and long-term outcomes in kidney transplant recipients with acute T cell-mediated rejection. <i>American Journal of Transplantation</i> , 2019, 19, 1972-1988.	2.6	60
52	Posttransplant Prophylactic Intravenous Immunoglobulin in Kidney Transplant Patients at High Immunological Risk: A Pilot Study. <i>American Journal of Transplantation</i> , 2007, 7, 1185-1192.	2.6	55
53	To Biopsy or Not to Biopsy? Should We Screen the Histology of Stable Renal Grafts?. <i>Transplantation</i> , 2007, 84, 671-676.	0.5	54
54	The spectrum of kidney biopsies in hospitalized patients with COVID-19, acute kidney injury and/or proteinuria. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1253-1262.	0.4	54

#	ARTICLE	IF	CITATIONS
55	Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor-Intolerant Graft Recipients of Kidneys From Extended-Criteria Donors. <i>American Journal of Transplantation</i> , 2016, 16, 2181-2186.	2.6	52
56	Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype. <i>American Journal of Transplantation</i> , 2016, 16, 2670-2675.	2.6	51
57	Genome-Wide Association Study of Acute Renal Graft Rejection. <i>American Journal of Transplantation</i> , 2017, 17, 201-209.	2.6	50
58	COVID-19 in Patients on Maintenance Dialysis in the Paris Region. <i>Kidney International Reports</i> , 2020, 5, 1535-1544.	0.4	49
59	Antiphospholipid syndrome and kidney disease. <i>Kidney International</i> , 2017, 91, 34-44.	2.6	44
60	mTOR inhibitors may benefit kidney transplant recipients with mitochondrial diseases. <i>Kidney International</i> , 2019, 95, 455-466.	2.6	44
61	Pharmacogenetics in Solid Organ Transplantation: Present Knowledge and Future Perspectives. <i>Transplantation</i> , 2004, 78, 311-315.	0.5	43
62	Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis. <i>Kidney International</i> , 2017, 92, 729-742.	2.6	43
63	Conversion to Belatacept in Maintenance Kidney Transplant Patients. <i>Transplantation</i> , 2018, 102, 1545-1552.	0.5	43
64	Recurrence from primary and secondary glomerulopathy after renal transplant. <i>Transplant International</i> , 2012, 25, 812-824.	0.8	42
65	Determinants and Outcomes of Accelerated Arteriosclerosis. <i>Circulation Research</i> , 2015, 117, 470-482.	2.0	41
66	Epitope load identifies kidney transplant recipients at risk of allosensitization following minimization of immunosuppression. <i>Kidney International</i> , 2019, 95, 1471-1485.	2.6	40
67	Trajectories of glomerular filtration rate and progression to end stage kidney disease after kidney transplantation. <i>Kidney International</i> , 2021, 99, 186-197.	2.6	40
68	Assessment of the Utility of Kidney Histology as a Basis for Discarding Organs in the United States: A Comparison of International Transplant Practices and Outcomes. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 397-409.	3.0	40
69	Eculizumab in renal transplantation. <i>Transplantation Reviews</i> , 2013, 27, 90-92.	1.2	39
70	Risk of Antibody-Mediated Rejection in Kidney Transplant Recipients With Anti-HLA-C Donor-Specific Antibodies. <i>American Journal of Transplantation</i> , 2014, 14, 1439-1445.	2.6	39
71	Restricted specificity of peripheral alloreactive memory B cells in HLA-sensitized patients awaiting a kidney transplant. <i>Kidney International</i> , 2015, 87, 1230-1240.	2.6	39
72	The emerging role of complement inhibitors in transplantation. <i>Kidney International</i> , 2015, 88, 967-973.	2.6	39

#	ARTICLE	IF	CITATIONS
73	Antimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004304.	1.3	38
74	Complement-binding anti-HLA antibodies are independent predictors of response to treatment in kidney recipients with antibody-mediated rejection. <i>Kidney International</i> , 2018, 94, 773-787.	2.6	38
75	Development and validation of an optimized integrative model using urinary chemokines for noninvasive diagnosis of acute allograft rejection. <i>American Journal of Transplantation</i> , 2020, 20, 3462-3476.	2.6	38
76	Prevalence and Predictors of Early Cardiovascular Events after Kidney Transplantation: Evaluation of Pre-Transplant Cardiovascular Work-Up. <i>PLoS ONE</i> , 2015, 10, e0131237.	1.1	38
77	Outcome of Kidney Transplantations Performed With Preformed Donor-Specific Antibodies of Unknown Etiology. <i>American Journal of Transplantation</i> , 2014, 14, 193-201.	2.6	37
78	Post-Transplant Natural Antibodies Associate with Kidney Allograft Injury and Reduced Long-Term Survival. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1761-1770.	3.0	36
79	Maintaining calcineurin inhibition after the diagnosis of post-transplant lymphoproliferative disorder improves renal graft survival. <i>Kidney International</i> , 2014, 85, 182-190.	2.6	35
80	Dual Kidney Transplantation: Is It Worth It?. <i>Transplantation</i> , 2017, 101, 488-497.	0.5	32
81	Management of Kaposi sarcoma after solid organ transplantation: A European retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 448-455.	0.6	31
82	Impact of estimation versus direct measurement of predonation glomerular filtration rate on the eligibility of potential living kidney donors. <i>Kidney International</i> , 2019, 95, 896-904.	2.6	31
83	Increased incidence and unusual presentations of CMV disease in kidney transplant recipients after conversion to belatacept. <i>American Journal of Transplantation</i> , 2021, 21, 2448-2458.	2.6	31
84	Estimated or Measured GFR in Living Kidney Donors Work-up?. <i>American Journal of Transplantation</i> , 2016, 16, 3024-3032.	2.6	30
85	Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis. <i>Transplant International</i> , 2017, 30, 1275-1283.	0.8	30
86	Decline and loss of anti-SARS-CoV-2 antibodies in kidney transplant recipients in the 6 months following SARS-CoV-2 infection. <i>Kidney International</i> , 2021, 99, 486-488.	2.6	30
87	Membranous Nephropathy Posttransplantation: An Update of the Pathophysiology and Management. <i>Transplantation</i> , 2019, 103, 1990-2002.	0.5	29
88	De Novo Donor-Specific Human Leukocyte Antigen Antibodies in Nonsensitized Kidney Transplant Recipients After T Cell-Mediated Rejection. <i>Transplantation</i> , 2015, 99, 965-972.	0.5	28
89	The age-calibrated measured glomerular filtration rate improves living kidney donation selection process. <i>Kidney International</i> , 2018, 94, 616-624.	2.6	28
90	Excellent long-term outcome of renal transplantation in cystinosis patients. <i>Orphanet Journal of Rare Diseases</i> , 2015, 10, 90.	1.2	27

#	ARTICLE	IF	CITATIONS
91	AKT/mTORC pathway in antiphospholipid-related vasculopathy: a new player in the game. <i>Lupus</i> , 2015, 24, 227-230.	0.8	27
92	Pathogenesis of non-HLA antibodies in solid organ transplantation: Where do we stand?. <i>Human Immunology</i> , 2016, 77, 1055-1062.	1.2	26
93	Solid Organ Transplantation in the Era of COVID-19: Lessons from France. <i>Transplantation</i> , 2021, 105, 61-66.	0.5	26
94	Propensity score–based comparison of the graft failure risk between kidney transplant recipients of standard and expanded criteria donor grafts: Toward increasing the pool of marginal donors. <i>American Journal of Transplantation</i> , 2018, 18, 1151-1157.	2.6	25
95	Dynamic prediction of renal survival among deeply phenotyped kidney transplant recipients using artificial intelligence: an observational, international, multicohort study. <i>The Lancet Digital Health</i> , 2021, 3, e795-e805.	5.9	25
96	Early treatment with sotrovimab monoclonal antibody in kidney transplant recipients with Omicron infection. <i>Kidney International</i> , 2022, 101, 1290-1293.	2.6	25
97	Reversal of Arterial Stiffness and Maladaptative Arterial Remodeling After Kidney Transplantation. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	24
98	HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients. <i>Kidney International</i> , 2021, 99, 671-685.	2.6	24
99	Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: proof-of-concept study. <i>BMJ Open</i> , 2021, 11, e052138.	0.8	24
100	Long-term CD4 lymphopenia is associated with accelerated decline of kidney allograft function. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 487-495.	0.4	23
101	Preemptive second kidney transplantation is associated with better graft survival compared with non-preemptive second transplantation: a multicenter French 2000-2014 cohort study. <i>Transplant International</i> , 2018, 31, 408-423.	0.8	22
102	A personalized follow-up of kidney transplant recipients using video conferencing based on a 1-year scoring system predictive of long term graft failure (TELEGRAFT study): protocol for a randomized controlled trial. <i>BMC Nephrology</i> , 2015, 16, 6.	0.8	21
103	Midterm Outcomes of 12 Renal Transplant Recipients Treated With Eculizumab to Prevent Atypical Hemolytic Syndrome Recurrence. <i>Transplantation</i> , 2017, 101, 2924-2930.	0.5	21
104	Efficacy and Safety of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant Recipients: Pooled Data From Three 12-Month Multicenter, Open-Label, Prospective Studies. <i>Transplantation Proceedings</i> , 2007, 39, 1386-1391.	0.3	20
105	Long-term outcome of methylmalonic aciduria after kidney, liver, or combined liver–kidney transplantation: The French experience. <i>Journal of Inherited Metabolic Disease</i> , 2020, 43, 234-243.	1.7	20
106	Reassessment of the clinical impact of preformed donor-specific anti-HLA-Cw antibodies in kidney transplantation. <i>American Journal of Transplantation</i> , 2020, 20, 1365-1374.	2.6	20
107	TRANSFORM: a novel study design to evaluate the effect of everolimus on long-term outcomes after kidney transplantation. <i>Open Access Journal of Clinical Trials</i> , 2014, , 45.	1.5	19
108	The costimulatory receptor B7-1 is not induced in injured podocytes. <i>Kidney International</i> , 2016, 90, 1037-1044.	2.6	18

#	ARTICLE	IF	CITATIONS
109	Conversion From Calcineurin Inhibitors to Belatacept in HLA-sensitized Kidney Transplant Recipients With Low-level Donor-specific Antibodies. <i>Transplantation</i> , 2019, 103, 2150-2156.	0.5	18
110	Acquired Flucytosine Resistance during Combination Therapy with Caspofungin and Flucytosine for <i>Candida glabrata</i> Cystitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 662-665.	1.4	17
111	Association of mGFR of the Remaining Kidney Divided by Its Volume before Donation with Functional Gain in mGFR among Living Kidney Donors. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1369-1376.	2.2	16
112	Temporal virus serological profiling of kidney graft recipients using VirScan. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 10899-10904.	3.3	16
113	Efficacy and Safety of Direct Oral Anticoagulants in Kidney Transplantation: A Single-center Pilot Experience. <i>Transplantation</i> , 2020, 104, 2625-2631.	0.5	15
114	Central nervous system complications in adult cystinosis patients. <i>Journal of Inherited Metabolic Disease</i> , 2020, 43, 348-356.	1.7	14
115	Use of computed tomography assessed kidney length to predict split renal GFR in living kidney donors. <i>European Radiology</i> , 2017, 27, 651-659.	2.3	13
116	Predictive Modeling of Tacrolimus Dose Requirement Based on High-Throughput Genetic Screening. <i>American Journal of Transplantation</i> , 2017, 17, 1008-1019.	2.6	13
117	Dynamic predictions of long-term kidney graft failure: an information tool promoting patient-centred care. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1961-1969.	0.4	13
118	GFR Assessment of Living Kidney Donors Candidates. <i>Transplantation</i> , 2019, 103, 1086-1093.	0.5	13
119	Prognosis of Invasive Aspergillosis in Kidney Transplant Recipients: A Case-Control Study. <i>Transplantation Direct</i> , 2016, 2, e90.	0.8	12
120	Poor Patient and Graft Outcome After Induction Treatment by Antithymocyte Globulin in Recipients of a Kidney Graft After Nonrenal Organ Transplantation. <i>Transplantation Direct</i> , 2018, 4, e357.	0.8	12
121	Safety of renal transplantation in patients with bipolar or psychotic disorders: a retrospective study. <i>Transplant International</i> , 2018, 31, 377-385.	0.8	12
122	Evidence-based practice: Guidance for using everolimus in combination with low-exposure calcineurin inhibitors as initial immunosuppression in kidney transplant patients. <i>Transplantation Reviews</i> , 2019, 33, 191-199.	1.2	12
123	Should kidney allografts from old donors be allocated only to old recipients?. <i>Transplant International</i> , 2020, 33, 849-857.	0.8	12
124	Renal transplantation outcomes in obese patients: a French cohort-based study. <i>BMC Nephrology</i> , 2021, 22, 79.	0.8	12
125	Mortality Prediction after the First Year of Kidney Transplantation: An Observational Study on Two European Cohorts. <i>PLoS ONE</i> , 2016, 11, e0155278.	1.1	12
126	Paraganglioma of the bladder in a kidney transplant recipient: A case report. <i>Molecular and Clinical Oncology</i> , 2017, 6, 553-555.	0.4	11

#	ARTICLE	IF	CITATIONS
127	Association of blood bicarbonate and pH with mineral metabolism disturbance and outcome after kidney transplantation. <i>American Journal of Transplantation</i> , 2020, 20, 1063-1075.	2.6	11
128	Temporal trends in living kidney donation in France between 2007 and 2017. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 730-738.	0.4	11
129	Lung cancer in renal transplant recipients: A case-control study. <i>Lung Cancer</i> , 2017, 111, 96-100.	0.9	10
130	Acyclovir in preventing cytomegalovirus infection in kidney transplant recipients: a case-controlled study. <i>Transplantation Proceedings</i> , 1993, 25, 1431-3.	0.3	10
131	The sexual dimorphism of kidney growth in mice and humans. <i>Kidney International</i> , 2022, 102, 78-95.	2.6	10
132	Proteinuria in kidney transplantation: an ongoing story. <i>Nature Reviews Nephrology</i> , 2013, 9, 251-252.	4.1	9
133	The Association Between Fibroblast Growth Factor-23 and Renal Transplantation Outcome Is Modified by Follow-up Duration and Glomerular Filtration Rate Assessment Method. <i>Kidney International Reports</i> , 2017, 2, 881-892.	0.4	9
134	The role of complement inhibition in kidney transplantation. <i>British Medical Bulletin</i> , 2017, 124, 1-13.	2.7	9
135	Comparison of graft and patient survival according to the transplantation centre policy for 1-year screening biopsy among stable kidney recipients: a propensity score-based study. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 703-711.	0.4	9
136	Deciphering the Prognostic and Predictive Value of Urinary CXCL10 in Kidney Recipients With BK Virus Reactivation. <i>Frontiers in Immunology</i> , 2020, 11, 604353.	2.2	9
137	The cost-effectiveness of prophylaxis with valaciclovir in the management of cytomegalovirus after renal transplantation. <i>European Journal of Health Economics</i> , 2005, 6, 172-182.	1.4	8
138	Determination of Lowest Possible Creatinine in Living-Donor Kidney Renal Transplant Recipients Based on Donor Kidney Function. <i>Transplantation</i> , 2008, 86, 558-563.	0.5	8
139	PREventing Delayed Graft Function by Driving Immunosuppressive Induction Treatment (PREDICT-DGF): study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 282.	0.7	8
140	No clinical benefit of rapid versus gradual tapering of immunosuppression to treat sustained <scp>BK</scp> virus viremia after kidney transplantation: a single-center experience. <i>Transplant International</i> , 2019, 32, 481-492.	0.8	8
141	Comparison of machine perfusion versus cold storage in kidney transplant recipients from expanded criteria donors: a cohort-based study. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1051-1059.	0.4	8
142	Time-dependent lymphocyte count after transplantation is associated with higher risk of graft failure and death. <i>Kidney International</i> , 2021, 99, 1189-1201.	2.6	8
143	Rituximab for recurrence of primary focal segmental glomerulosclerosis after kidney transplantation: Results of a nationwide study. <i>American Journal of Transplantation</i> , 2021, 21, 3021-3033.	2.6	8
144	Induction therapy in kidney transplant recipients: Description of the practices according to the calendar period from the French multicentric DIVAT cohort. <i>PLoS ONE</i> , 2020, 15, e0240929.	1.1	8

#	ARTICLE	IF	CITATIONS
145	CRISPR/Cas9-Engineered HLA-Deleted Glomerular Endothelial Cells as a Tool to Predict Pathogenic Non-HLA Antibodies in Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology</i> , 2021, 32, 3231-3251.	3.0	8
146	Acyclovir in preventing cytomegalovirus infection in kidney transplant recipients: A case-controlled study. <i>Journal of Medical Virology</i> , 1993, 41, 118-122.	2.5	7
147	Renal safety of high-dose, sucrose-free intravenous immunoglobulin in kidney transplant recipients: an observational study. <i>Transplant International</i> , 2016, 29, 1205-1215.	0.8	7
148	Reduction in late onset cytomegalovirus primary disease after discontinuation of antiviral prophylaxis in kidney transplant recipients treated with de novo everolimus. <i>Transplant Infectious Disease</i> , 2018, 20, e12846.	0.7	7
149	Encrusted Urinary Tract Infections Due to <i>Corynebacteria</i> Species. <i>Kidney International Reports</i> , 2021, 6, 179-186.	0.4	7
150	CD25 blockade in kidney transplant patients randomized to standard-dose or high-dose basiliximab with cyclosporine, or high-dose basiliximab in a calcineurin inhibitor-free regimen. <i>Transplant International</i> , 2016, 29, 184-195.	0.8	6
151	What is the significance of end-stage renal disease risk estimation in living kidney donors?. <i>Transplant International</i> , 2017, 30, 799-806.	0.8	6
152	Osmoregulation Performance and Kidney Transplant Outcome. <i>Journal of the American Society of Nephrology</i> : JASN, 2019, 30, 1282-1293.	3.0	6
153	PRODIG (Prevention of new onset diabetes after transplantation by a short term treatment of) Tj ETQq1 1 0.784314 rgBT /Overlock 1 controlled study. <i>Trials</i> , 2019, 20, 375.	0.7	6
154	Comparison of Postdonation Kidney Function Between Caucasian Donors and Low-risk APOL1 Genotype Living Kidney Donors of African Ancestry. <i>Transplantation</i> , 2018, 102, e462-e463.	0.5	5
155	Dissociation of humoral and cellular immune responses in kidney transplant recipients with EBV mucocutaneous ulcer. <i>Transplant Infectious Disease</i> , 2021, 23, e13552.	0.7	5
156	Ravulizumab for the Treatment of aHUS in Adults: Improving Quality of Life. <i>Kidney International Reports</i> , 2021, 6, 1489-1491.	0.4	5
157	Kidney transplantation from expanded criteria donors: an increased risk of urinary complications “the UriNary Complications Of Renal Transplant (UNyCORT) study. <i>BJU International</i> , 2022, 129, 225-233.	1.3	5
158	The First Transplant Kidney Biopsy Ever Performed. <i>American Journal of Transplantation</i> , 2013, 13, 1367-1368.	2.6	4
159	Conversion From Belatacept to Another Immunosuppressive Regimen in Maintenance Kidney-Transplantation Patients. <i>Kidney International Reports</i> , 2020, 5, 2195-2201.	0.4	4
160	The weekend effect in kidney transplantation outcomes: a French cohort-based study. <i>Transplant International</i> , 2020, 33, 1030-1039.	0.8	4
161	Timing of Kidney Clamping and Deceased Donor Kidney Transplant Outcomes. <i>Clinical Journal of the American Society of Nephrology</i> : CJASN, 2021, 16, 1704-1714.	2.2	4
162	Sequential measurements of urinary albumin in recipients of renal allografts. <i>Clinical Chemistry</i> , 1991, 37, 472-473.	1.5	3

#	ARTICLE	IF	CITATIONS
163	Generation of Catalytic Antibodies Is an Intrinsic Property of an Individual's Immune System: A Study on a Large Cohort of Renal Transplant Patients. <i>Journal of Immunology</i> , 2016, 196, 4075-4081.	0.4	3
164	Lifetime ESKD risk stratification for living kidney donor studies. <i>American Journal of Transplantation</i> , 2019, 19, 2658-2659.	2.6	3
165	Lack of impact of pre-emptive deceased-donor kidney transplantation on graft outcomes: a propensity score-based study. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 886-891.	0.4	3
166	Predictive value of mixed antigen screen beads in pre-transplant assessment of HLA immunization in solid organ transplant recipients. <i>Clinical Transplantation</i> , 2020, 34, e14002.	0.8	3
167	Management of post-transplant recurrent focal and segmental glomerulosclerosis. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1994-1996.	0.4	3
168	Ig-responsive relapsing inflammatory syndrome following COVID-19 in a kidney transplant recipient. <i>Kidney International</i> , 2021, 99, 767-768.	2.6	3
169	Living kidney donor evaluation for all candidates with normal estimated GFR for age. <i>Transplant International</i> , 2021, 34, 1123-1133.	0.8	3
170	Antibody-mediated vascular rejection of kidney allograft: characterization of different kidney allograft rejection phenotypes via histology, C4d deposition and donor-specific antibodies. <i>Clinical and Experimental Immunology</i> , 2014, 178, 59-60.	1.1	2
171	A Test Identifying Biomarkers of Immunosuppression-Related Adverse Events in Kidney Transplant Recipients. <i>Kidney International Reports</i> , 2019, 4, 1664-1665.	0.4	2
172	Baseline graft status is a critical predictor of kidney graft failure after diarrhoea. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1597-1604.	0.4	2
173	Outcomes of kidney-transplanted patients with history of intestinal reconstruction of the urinary tract. <i>BJU Compass</i> , 2022, 3, 75-85.	0.7	2
174	Editorial: Transplantation of Marginal Organs' Immunological Aspects and Therapeutic Perspectives. <i>Frontiers in Immunology</i> , 2020, 11, 612576.	2.2	2
175	Erythrocytosis associated with IgA nephropathy. <i>EBioMedicine</i> , 2022, 75, 103785.	2.7	2
176	Poor kidney graft survival in anorexia nervosa patients. <i>Eating and Weight Disorders</i> , 2021, 26, 1447-1455.	1.2	1
177	A kidney discard decision strategy based on zero-time histology analysis could lead to an unjustified increase in the organ turndown rate among ECD. <i>Transplant International</i> , 2021, 34, 1506-1516.	0.8	1
178	The Case Membranous nephropathy after alemtuzumab treatment. <i>Kidney International</i> , 2021, 100, 249-250.	2.6	1
179	Cohort study: Outcomes of kidney transplantation in patients with prosthetic heart valves. <i>Transplant International</i> , 2021, 34, 2297-2304.	0.8	1
180	COVID-19: A One-center Experience in Paris. <i>Transplantation Direct</i> , 2021, 7, e647.	0.8	1

#	ARTICLE	IF	CITATIONS
181	Long-term survival benefit from dual kidney transplantation using kidneys from donors with very extended criteria—a French cohort between 2002 and 2014. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 982-990.	0.4	1
182	First dose OKT3-induced release of endothelin in renal transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 0, , .	0.4	0
183	Response to: “Renal allograft histology at 10 years after transplantation in the tacrolimus era: Evidence of pervasive chronic injury” <i>American Journal of Transplantation</i> , 2018, 18, 1292-1292.	2.6	0
184	FP742 THE IMPACT OF AGE ON ACCEPTABLE MEASURED GFR FOR LIVING KIDNEY DONATION. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i296-i296.	0.4	0
185	FO051 THE IMPACT OF GFR EVALUATION TECHNIQUE ON LIVING KIDNEY DONATION ELIGIBILITY. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i39-i40.	0.4	0
186	The Case Posttransplant upper limb inflammatory nodules. <i>Kidney International</i> , 2019, 95, 721-722.	2.6	0
187	FC 055 PERCENTILES OF NORMAL MEASURED GLOMERULAR FILTRATION RATE BASED ON DATA FROM LIVING KIDNEY DONORS. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
188	The Case Cardiac tamponade in a kidney transplant recipient with chronic inflammation. <i>Kidney International</i> , 2021, 100, 487-488.	2.6	0
189	Outcome of pretransplant melanoma after solid organ transplantation: an observational study. <i>Transplant International</i> , 2021, 34, 2154-2165.	0.8	0
190	Cancer After Kidney Transplantation. , 2017, , 525-542.		0
191	MO1021: Long-Term Outcomes After Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant: A Matched Cohort Study. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	0
192	FC 105: Multidimensional Prognostication Tool for Kidney Transplant Patient Survival: The Mortality Mbox. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	0